

IFN alpha Rabbit pAb

Catalog # AP96810

Product Information

Application	WB, E
Predicted	Mouse
Host	Rabbit
Clonality	Polyclonal
Calculated MW	22 KDa
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from mouse IFN alpha 1b
Epitope Specificity	101-189/189
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SIMILARITY	Belongs to the alpha/beta interferon family.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	The protein encoded by this gene is produced by macrophages and has antiviral activity. This gene is intronless and the encoded protein is secreted. [provided by RefSeq, Sep 2011] The type I interferons consist of 14 different alpha isoforms (subtypes with slightly different specificities), and single beta, omega, epsilon and kappa isoforms. Homologous molecules are found in many species, including rats and mice (and most mammals), and have been identified in birds, reptiles and fish species. Interferon alpha is produced primarily by plasmacytoid dendritic cells and is a potent component of the anti viral innate immune response; it modulates adaptive immunity.

Additional Information

Other Names	IFL; IFN; IFN-ALPHA; IFN-alphaD; IFNA13; IFNA@; leIF D; IFNA1_HUMAN; IFNA1; IFN-alpha-1/13; Interferon alpha-D (leIF D); interferon alpha 1; IFN-alpha 1b; interferon alpha 1b
Dilution	WB=1:500-2000,ICC/IF=1:100-500,ELISA=1:5000-10000
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Name	IFN alpha Rabbit pAb
Function	Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.